Search peptides, terms, sources/
Glossary

Yellow Card Scheme

The UK’s system for reporting suspected side effects (adverse drug reactions) from medicines and other healthcare products, run by the MHRA. Reporting to the Yellow Card scheme is voluntary and is known to under-represent the true number of side effects that occur, so the MHRA itself cautions that a Yellow Card count does not establish how common a side effect actually is, or confirm that a reported reaction was actually caused by the product named in the report.

Peptides where this matters

  • Melanotan IIMT-II

    Synthetic melanocortin receptor agonist studied for skin tanning. Not licensed in the UK; human evidence is a three-volunteer pilot plus case reports.

    MelanocortinHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine

All glossary terms

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.